229 related articles for article (PubMed ID: 28455002)
1. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
2. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
Skildum A; Dornfeld K; Wallace K
Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression.
Minoia M; Gentilin E; Molè D; Rossi M; Filieri C; Tagliati F; Baroni A; Ambrosio MR; degli Uberti E; Zatelli MC
J Clin Endocrinol Metab; 2012 Jun; 97(6):E907-16. PubMed ID: 22442272
[TBL] [Abstract][Full Text] [Related]
5. N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation.
Liu Y; Liu R; Fu P; Du F; Hong Y; Yao M; Zhang X; Zheng S
Cell Physiol Biochem; 2015; 36(6):2494-503. PubMed ID: 26279450
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression.
Huang Y; Jiang D; Sui M; Wang X; Fan W
Oncol Rep; 2017 Feb; 37(2):705-712. PubMed ID: 28000875
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
Exp Cell Res; 2013 Dec; 319(20):3140-9. PubMed ID: 24012960
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
9. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
10. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
12. Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model.
Ozcelikkale A; Shin K; Noe-Kim V; Elzey BD; Dong Z; Zhang JT; Kim K; Kwon IC; Park K; Han B
J Control Release; 2017 Nov; 266():129-139. PubMed ID: 28939108
[TBL] [Abstract][Full Text] [Related]
13. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
[TBL] [Abstract][Full Text] [Related]
14. Growth factors and chemotherapeutic modulation of breast cancer cells.
Ciftci K; Su J; Trovitch PB
J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904
[TBL] [Abstract][Full Text] [Related]
15. Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells.
Chen WC; Lai YA; Lin YC; Ma JW; Huang LF; Yang NS; Ho CT; Kuo SC; Way TD
J Agric Food Chem; 2013 Dec; 61(48):11817-24. PubMed ID: 24236784
[TBL] [Abstract][Full Text] [Related]
16. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
Eur J Pharm Sci; 2018 Oct; 123():56-69. PubMed ID: 30016648
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
[TBL] [Abstract][Full Text] [Related]
20. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Satram-Maharaj T; Nyarko JN; Kuski K; Fehr K; Pennington PR; Truitt L; Freywald A; Lukong KE; Anderson DH; Mousseau DD
Cell Signal; 2014 Dec; 26(12):2621-32. PubMed ID: 25152370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
